vs
Side-by-side financial comparison of Rimini Street, Inc. (RMNI) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Rimini Street, Inc. is the larger business by last-quarter revenue ($105.5M vs $60.1M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). Rimini Street, Inc. runs the higher net margin — 1.3% vs -92.6%, a 93.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 1.2%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 1.1%).
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RMNI vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $60.1M |
| Net Profit | $1.4M | $-55.6M |
| Gross Margin | 59.0% | 88.1% |
| Operating Margin | 4.6% | -87.1% |
| Net Margin | 1.3% | -92.6% |
| Revenue YoY | 1.2% | 83.8% |
| Net Profit YoY | -59.4% | — |
| EPS (diluted) | $0.01 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $105.5M | $60.1M | ||
| Q4 25 | $109.8M | $57.3M | ||
| Q3 25 | $103.4M | $51.3M | ||
| Q2 25 | $104.1M | $48.5M | ||
| Q1 25 | $104.2M | $32.7M | ||
| Q4 24 | $114.2M | $41.8M | ||
| Q3 24 | $104.7M | $33.3M | ||
| Q2 24 | $103.1M | $29.1M |
| Q1 26 | $1.4M | $-55.6M | ||
| Q4 25 | $724.0K | $-47.5M | ||
| Q3 25 | $2.8M | $-52.9M | ||
| Q2 25 | $30.3M | $-46.6M | ||
| Q1 25 | $3.4M | $-49.5M | ||
| Q4 24 | $6.7M | $-43.3M | ||
| Q3 24 | $-43.1M | $-43.6M | ||
| Q2 24 | $-1.1M | $-32.3M |
| Q1 26 | 59.0% | 88.1% | ||
| Q4 25 | 60.4% | 91.6% | ||
| Q3 25 | 59.9% | 89.3% | ||
| Q2 25 | 60.4% | 88.6% | ||
| Q1 25 | 61.0% | 88.8% | ||
| Q4 24 | 63.7% | 90.9% | ||
| Q3 24 | 60.7% | 88.5% | ||
| Q2 24 | 59.1% | 89.9% |
| Q1 26 | 4.6% | -87.1% | ||
| Q4 25 | 4.5% | -82.2% | ||
| Q3 25 | 4.2% | -102.6% | ||
| Q2 25 | 39.6% | -93.4% | ||
| Q1 25 | 9.0% | -143.7% | ||
| Q4 24 | 13.0% | -98.6% | ||
| Q3 24 | -47.4% | -132.0% | ||
| Q2 24 | -0.8% | -139.2% |
| Q1 26 | 1.3% | -92.6% | ||
| Q4 25 | 0.7% | -83.0% | ||
| Q3 25 | 2.7% | -103.1% | ||
| Q2 25 | 29.1% | -96.1% | ||
| Q1 25 | 3.2% | -151.4% | ||
| Q4 24 | 5.8% | -103.6% | ||
| Q3 24 | -41.2% | -131.2% | ||
| Q2 24 | -1.1% | -110.9% |
| Q1 26 | $0.01 | $-0.83 | ||
| Q4 25 | $0.00 | $-0.73 | ||
| Q3 25 | $0.03 | $-0.82 | ||
| Q2 25 | $0.32 | $-0.75 | ||
| Q1 25 | $0.04 | $-0.81 | ||
| Q4 24 | $0.07 | $-0.71 | ||
| Q3 24 | $-0.47 | $-0.73 | ||
| Q2 24 | $-0.01 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $132.2M | $340.6M |
| Total DebtLower is stronger | $56.4M | — |
| Stockholders' EquityBook value | — | $122.9M |
| Total Assets | $397.1M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $132.2M | $340.6M | ||
| Q4 25 | $120.0M | $388.9M | ||
| Q3 25 | $108.7M | $416.1M | ||
| Q2 25 | $101.3M | $291.0M | ||
| Q1 25 | $122.6M | $314.5M | ||
| Q4 24 | $88.8M | $320.6M | ||
| Q3 24 | $119.5M | $298.4M | ||
| Q2 24 | $134.2M | $319.1M |
| Q1 26 | $56.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $-27.0M | $139.1M | ||
| Q3 25 | $-27.3M | $148.8M | ||
| Q2 25 | $-29.0M | $-11.9M | ||
| Q1 25 | $-63.7M | $18.9M | ||
| Q4 24 | $-69.4M | $21.7M | ||
| Q3 24 | $-76.8M | $11.2M | ||
| Q2 24 | $-36.1M | $39.3M |
| Q1 26 | $397.1M | $442.3M | ||
| Q4 25 | $423.1M | $480.2M | ||
| Q3 25 | $352.9M | $506.9M | ||
| Q2 25 | $397.5M | $372.7M | ||
| Q1 25 | $343.0M | $386.7M | ||
| Q4 24 | $369.1M | $392.3M | ||
| Q3 24 | $343.8M | $363.6M | ||
| Q2 24 | $367.4M | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
